BioMarin Pharmaceutical
Unlock to Claim this listing
Add / Modify Company
BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today. Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies. Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.
3.82
Overall Excellence Rating
Industry
Gas & Mining, OilCategory
Biotechnology ResearchESG/Ethical Impact
BioMarin Pharmaceutical takes decisive strides toward environmental stewardship by integrating sustainable strategies across its operations, encompassing energy-efficient manufacturing, responsible supply chain management, waste reduction initiatives, and sustainable packaging solutions, all strategically aimed at reducing its ecological footprint and promoting a culture of environmental responsibility that echoes its core mission of contributing to a healthier planet. A vanguard of positive social impact, BioMarin Pharmaceutical elevates its role in transforming lives through rare disease therapies, channeling its innovative product portfolio toward addressing unmet medical needs, while actively engaging in patient support initiatives, community collaborations, and healthcare education programs, thus fostering a holistic and meaningful approach to societal well-being. BioMarin Pharmaceutical’s unwavering commitment to research excellence and innovation underpins its ESG sustainability strategy, as it persistently advances pioneering therapies that address rare diseases, improve patient outcomes, and drive medical science forward, all while maintaining a steadfast adherence to the highest ethical standards, research integrity, and a patient-centric ethos that underscores its pivotal role in transforming healthcare landscapes. The bedrock of BioMarin Pharmaceutical’s ESG framework rests upon a foundation of exemplary governance practices, underscored by a culture of transparency, integrity, and accountability that permeates its decision-making processes, facilitated by a diverse and experienced board of directors, rigorous compliance protocols, and ethical conduct that positions the company as a model of responsible corporate leadership. BioMarin Pharmaceutical’s financial sustainability harmoniously intertwines with its ESG imperatives, as its financial growth is inextricably linked to its ability to develop and provide groundbreaking rare disease treatments that resonate with patients, healthcare professionals, and investors who recognize the inherent value of responsible innovation and sustainable business practices. BioMarin Pharmaceutical’s stakeholder engagement philosophy thrives on inclusivity and collaboration, extending to patients, healthcare professionals, employees, communities, and investors, fostering an environment of open dialogue, attentive listening, and transparent communication that shapes its strategies, aligns with societal aspirations, and underscores its unwavering dedication to advancing healthcare and societal well-being.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
2311000000
Website Traffic
Employee Rating
4.2
Customer Rating
4
Company Size
1000-5000
ESG Risk Rating
3